Sarepta Therapeutics (SRPT) PT Raised to $176 at BofA Securities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rises after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
- Intel shares fall as competitor reports record results
- Array Technologies and Shoals Technologies agree to stock-for-stock merger
- AMD gets bullish pre-earnings call from Lynx as server CPU demand accelerates
- Marathon Petroleum to sell two refineries to CVR Energy for $4.2B
- SanDisk shares fall on election and chip sector pressure
- After-Hours Movers: AMD, SMCI, SWKS, NRIX, TOST, BKNG
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
Sarepta Therapeutics (SRPT) to resume trading at 7:10AM ET following a positive FDA AdCom vote
May 15, 2023 6:51 AM EDTSarepta Therapeutics (NASDAQ: SRPT) is set to resume trading at 7:10AM ET following a positive FDA AdCom vote on DMD treatment SRP-9001.
... MoreSarepta (SRPT) could jump 30%+ following positive AdCom on DMD treatment SRP-9001
May 15, 2023 6:39 AM EDT(Updated - May 15, 2023 6:40 AM EDT)
Shares of Sarepta Therapeutics, Inc. (NASDAQ: SRPT), which are currently halted, are set to open higher Monday following a positive FDA Advisory Committee vote for Duchenne muscular dystrophy gene therapy treatment SRP-9001. One analyst thinks the stock can jump 33% today amid the news.
In a close vote 8 to 6 vote, the FDA U.S. Food and Drug Administration (FDA) Cellular, Tissue and Gene... More



